flunisolide (Nasalide, Nasarel AeroBid)
Jump to navigation
Jump to search
Introduction
Tradenames: Nasalide, AeroBid.
Indications
- seasonal or perennial rhinitis
- prophylaxis for asthma
- chronic bronchitis & COPD
- atopy[6]
Dosage
Pharmacokinetics
onset of action is 1-4 weeks
elimination via liver
1/2life = 1.8 hours
Adverse effects
- common (> 10%)
- bitter taste, nervousness, headache, hoarseness, GI irritation, oral candidiasis, increased susceptibility to infection, dizziness, anorexia, coughing, upper respiratory tract infection, pounding heartbeat, menstrual problems, itching, rash, bronchitis
- less common (1-10%)
- epistaxis, insomnia, diaphoresis, increased appetite, dry mouth & throat, psychic changes, acne, hives, cataracts, loss of smell & taste
- uncommon (< 1%)
- bronchospasm, shortness of breath, abdominal fullness
- other
- irritation of nasal mucosa
- rarely nasal ulceration
- oral candidiasis (thrush)
Laboratory
Mechanism of action
- inhaler
- no significant cortisol suppression at 2 mg/day (8 puffs)
- no effect on bone density after 1 year at 1 mg/day (4 puffs)
- nasal preparation
- does NOT inhibit IgE synthesis or mast cell degranulation
- inhibits cytokine production, arachidonate metabolism, inflammation & mast cell proliferation
More general terms
References
- ↑ The Pharmacological Basis of Therapeutics, 9th ed. Gilman et al, eds. Permagon Press/McGraw Hill, 1996
- ↑ Saunders Manual of Medical Practice, Rakel (ed), WB Saunders, Philadelphia, 1996, pg 85
- ↑ Forest Pharmaceuticals
- ↑ Mayo Internal Medicine Board Review, 1998-99, Prakash UBS (ed) Lippincott-Raven, Philadelphia, 1998, pg 743
- ↑ Kaiser Permanente Northern California Regional Drug Formulary, 1998
- ↑ 6.0 6.1 Deprecated Reference
- ↑ Department of Veterans Affairs, VA National Formulary